Thromboembolic and bleeding complications in acute leukemia

Expert Review of Hematology

Volumn 3, Issue 6, 2010, Pages 719-730

  Kwaan, Hau C ^a   Huyck, Timothy ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

acute leukemia; acute promyelocytic leukemia; anticoagulation; fibrinolysis; hemorrhage; leukostasis; platelet transfusion; thrombosis

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ARSENIC TRIOXIDE; ASPARAGINASE; CALICHEAMICIN; CORTICOSTEROID; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; GEMTUZUMAB OZOGAMICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITHRAMYCIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID; THALIDOMIDE; TIOGUANINE; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNINDEXED DRUG; URETHAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IATROGENIC DISEASE; INCIDENCE; LEUKOSTASIS; LIVER VEIN THROMBOSIS; LUNG EMBOLISM; LUNG HEMORRHAGE; LYMPHOMA; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ACUTE DISEASE; BLOOD VESSELS; DRUG THERAPY; HEMORRHAGE; HUMANS; LEUKEMIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 78649498409     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.71     Document Type: Review

References (132)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. Balliere, Paris, France, 654-712 (1865).
2. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J. Clin. Oncol. 1027(29), 4839-4847 (2009).
3. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med. 119(1), 60-68 (2006). (Pubitemid 43117468)
4. Mohren M, Markmann I, Jentsch- Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia. Br. J. Cancer 94(2), 200-202 (2006).
5. De Stefano V, Sora F, Rossi E et al. The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. J. Thromb. Haemost. (9), 1985-1992 (2005).
6. Ziegler S, Sperr WR, Knobl P et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb. Res. 115(1-2), 59-64 (2005).
7. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival. Blood 113(17), 3911-3917 (2009).
8. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91(11), 1530-1537 (2006).
9. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb. Res. 111(3), 125-131 (2003).
10. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br. J. Haematol. 138(4), 430-445 (2007).
11. Caruso V, Iacoviello L, Di Castelnuovo A et al. Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108(7), 2216-2222 (2006).
12. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: Results from a meta-analysis. J. Thromb. Haemost. 5(3), 621-623 (2007).
13. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of the disease and therapy. Thromb. Res. 111(4-5), 199-212 (2003).
14. Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin. Thromb. Hemost. 33(4), 355-364 (2007).
15. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of host environment. Thromb. Res. 111(6), 321-327 (2003).
16. Virchow R. Phlogose und thrombose in gefabsystem. In: Gesammelte Abhandlungen Zur Wissenschaftlichen Medizin. Von Meidinger Sohn, Frankfurt, Germany, 458-636 (1856).
17. Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: Lack of correlation between degree of cytoreduction and early mortality rate. Br. J. Haematol. 98(2), 433-436 (1997). Describes the clinical findings on leukapheresis in hyperleukocytosis and provides the argument against the use of this approach in the management of this condition.
18. Vaughan WP, Kimball AW, Karp JE, Dragon LH, Burke PJ. Factors affecting survival of patients with acute myelocytic leukemia presenting with high WBC counts. Cancer Treat. Rep. 65(11-12), 1007-1013 (1981).
19. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 60(12), 3071-3079 (1987).
20. Cuttner J, Conjalka MS, Reilly M et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am. J. Med. 69(4), 555-558 (1980).
21. Scott CS, Stark AN, Limbert HJ, Master PS, Head C, Roberts BE. Diagnostic and prognostic factors in acute monocytic leukaemia: An analysis of 51 cases. Br. J. Haematol. 69(2), 247-252 (1988).
22. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: A new association. Blood 61(5), 994-998 (1983).
23. Vahdat L, Maslak P, Miller WH Jr et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-a isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84(11), 3843-3849 (1994).
24. Archimbaud E, Charrin C, Magaud JP et al. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: Confirmation of the existence of different entities with 11q23 breakpoint. Leukemia 12(1), 25-33 (1998).
25. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 96(1), 24-33 (2000).
26. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: Molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 97(7), 2121-2129 (2001).
27. Marbello L, Ricci F, Nosari AM et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature. Leuk. Res. 32(8), 1221-1227 (2008).
28. Thiebaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann. Hematol. 79(9), 501-506 (2000).
29. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 14(Suppl.1), 23-32 (2008).
30. DeLeve LD. Hepatic microvasculature in liver injury. Semin. Liver Dis. 27(4), 390-400 (2007).
31. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Update on defibrotide and other current investigational therapies. Bone Marrow Transplant 41(3), 229-237 (2008).
32. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347(6293), 558-561 (1990).
33. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am. Soc. Hematol. Educ. Program 156-161 (2006).
34. Licht JD. Acute promyelocytic leukemia - weapons of mass differentiation. N. Engl. J. Med. 360(9), 928-930 (2009). A concise summary of the molecular basis of acute promyelocytic leukemia (APL).
35. Neame PB, Soamboonsrup P, Leber B et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants. Am. J. Hematol. 56(3), 131-142 (1997).
36. Rizzatti EG, Portieres FL, Martins SL, Rego EM, Zago MA, Falcao RP. Microgranular and t(11;17)/PLZF-RARa variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARa gene rearrangement. Am. J. Hematol. 76(1), 44-51 (2004).
37. Sanz MA, Grimwade D, Tallman MS et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113(9), 1875-1891 (2009).
38. Wang ZY, Chen Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111(5), 2505-2515 (2008).
39. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75(11), 2112-2117 (1990).
40. Stein E, McMahon B, Kwaan HC, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract. Res. Clin. Haematol. 22(1), 153-163 (2009).
41. Jacomo RH, Melo RA, Souto FR et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92(10), 1431-1432 (2007).
42. Watanabe R, Murata M, Takayama N et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS). Thromb. Haemost. 77(4), 641-645 (1997).
43. Dombret H, Scrobohaci ML, Ghorra P et al. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment. Leukemia 7(1), 2-9 (1993).
44. Tallman MS, Lefebvre P, Baine RM et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J. Thromb. Haemost. 2(8), 1341-1350 (2004).
45. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: Fibrinolysis due to u-PA rather than defibrination. Br. J. Haematol. 71(4), 511-517 (1989).
46. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77(9), 1949-1957 (1991).
47. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired a-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br. J. Haematol. 70(1), 43-48 (1988).
48. Falanga A, Iacoviello L, Evangelista V et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 86(3), 1072-1081 (1995).
49. Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br. J. Haematol. 108(4), 689-695 (2000).
50. de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111(7), 3395-3402 (2008).
51. Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am. Soc. Hematol. Educ. Program 151-157 (2007).
52. Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin. Thromb. Hemost. 33(4), 330-338 (2007). Detailed review of the thrombotic and bleeding complications in APL.
53. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk. Lymphoma 20(5-6), 435-439 (1996).
54. Goldschmidt N, Gural A, Ben Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia. Leuk. Lymphoma 44(8), 1433-1437 (2003).
55. Breccia M, Avvisati G, Latagliata R et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 21(1), 79-83 (2007).
56. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia - a single center experience in 34 patients. Thromb. Res. 116(2), 109-114 (2005).
57. Polliack A. Acute promyelocytic leukemia with disseminated intravascular coagulation. Am. J. Clin. Pathol. 56(2), 155-161 (1971).
58. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79(3), 543-553 (1992).
59. Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: Not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia. Blood 79(2), 534-535 (1992).
60. Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 87(2), 613-617 (1996). (Pubitemid 26030316)
61. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J. Cell Biol. 109(1), 389-395 (1989).
62. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine. Biochemistry 25(14), 4007-4020 (1986).
63. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br. J. Haematol. 115(2), 382-391 (2001). Describes the basis of increased tissue factor activation in apoptosis.
64. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N. Engl. J. Med. 340(13), 994-1004 (1999). The first description on the increased expression of annexin II in acute promyelocytic leukemia in both the NB4 cell line and the human APL promyelocytes.
65. Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J. Thromb. Haemost. 2(2), 306-312 (2004).
66. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb. Haemost. 100(6), 969-975 (2008).
67. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract. Res. Clin. Haematol. 16(3), 463-482 (2003).
68. Sanz MA, Martin G, Gonzalez M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-transretinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 3(4), 1237-1243 (2004). (Pubitemid 38168633)
69. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105(8), 3019-3025 (2005).
70. Sanz MA. Treatment of acute promyelocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program 147-155 (2006). Important guidelines in the management of APL provided by a team of experts.
71. Lijfering WM, Brouwer JL, Veeger NJ et al. Selective testing for thrombophilia in patients with first venous thrombosis: Results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113(21), 5314-5322 (2009).
72. Gomez-Puerta JA, Cervera R, Espinosa G et al. Antiphospholipid antibodies associated with malignancies: Clinical and pathological characteristics of 120 patients. Semin. Arthritis Rheum. 35(5), 322-332 (2006).
73. Miesbach W, Asherson RA, Cervera R et al. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev. 6(2), 94-97 (2006). (Pubitemid 44810182)
74. Freytes CO. Thromboembolic complications related to central venous access catheters in cancer patients. Semin. Thromb. Hemost. 33(4), 389-396 (2007).
75. Freytes CO. Catheter-related thrombosis. Cancer Treat. Res. 148,207-221 (2009). The most comprehensive review on the pathogenesis and management of catheter-related thrombosis.
76. Xiang DZ, Verbeken EK, Van Lommel AT, Stas M, De Wever I. Composition and formation of the sleeve enveloping a central venous catheter. J. Vasc. Surg. 28(2), 260-271 (1998).
77. Forauer AR, Theoharis CG, Dasika NL. Jugular vein catheter placement: Histologic features and development of catheterrelated (fibrin) sheaths in a swine model. Radiology 240(2), 427-434 (2006).
78. De Cicco M, Matovic M, Balestreri L et al. Central venous thrombosis: An early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb. Res. 86(2), 101-113 (1997).
79. Barzaghi A, Dell'Orto M, Rovelli A, Rizzari C, Colombini A, Uderzo C. Central venous catheter clots: Incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr. Hematol. Oncol. 12(3), 243-250 (1995).
80. Couban S, Goodyear M, Burnell M et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J. Clin. Oncol. 23(18), 4063-4069 (2005).
81. Lee AY, Levine MN, Butler G et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J. Clin. Oncol. 24(9), 1404-1408 (2006).
82. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 9(2), 207-216 (2004).
83. Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb. Haemost. 75(2), 251-253 (1996).
84. Munoz FJ, Mismetti P, Poggio R et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: Results from the RIETE Registry. Chest 133(1), 143-148 (2008).
85. Verso M, Agnelli G, Bertoglio S et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebocontrolled, randomized study in cancer patients. J. Clin. Oncol. 23(18), 4057-4062 (2005).
86. Karthaus M, Kretzschmar A, Kroning H et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebocontrolled Phase III trial. Ann. Oncol. 17(2), 289-296 (2006).
87. Jones MA, Lee DY, Segall JA et al. Characterizing resolution of catheterassociated upper extremity deep venous thrombosis. J. Vasc. Surg. 51(1), 108-113 (2009).
88. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 381S-453S (2008).
89. Huisman MV. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups. J. Thromb. Haemost. 4(1), 10-13 (2006).
90. Sabeti S, Schillinger M, Mlekusch W, Haumer M, Ahmadi R, Minar E. Treatment of subclavian-axillary vein thrombosis: Long-term outcome of anticoagulation versus systemic thrombolysis. Thromb. Res. 108(5-6), 279-285 (2002).
91. Schindler J, Bona RD, Chen HH et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clin. Appl. Thromb. Hemost. 5(1), 25-29 (1999).
92. Kim HS, Preece SR, Black JH, Pham LD, Streiff MB. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J. Vasc. Surg. 47(2), 388-394 (2008).
93. Bennett CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ. Adverse effects of drugs used to treat hematologic malignancies: Surveillance efforts from the research on adverse drug events and reports project. Semin. Thromb. Hemost. 33(4), 365-372 (2007).
94. Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving l-asparaginase. Am. J. Hematol. 47(3), 157-161 (1994).
95. Nowak-Gottl U, Rath B, Binder M et al. Inefficacy of fresh frozen plasma in the treatment of l-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 80(5), 451-453 (1995).
96. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus. Med. Rev. 18(3), 153-167 (2004).
97. Mitchell L, Andrew M, Hanna K et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb. Haemost. 90(2), 235-244 (2003).
98. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 5(6), 484-487 (2003).
99. Kucuk O, Kwaan HC, Gunnar W, Vazquez RM. Thromboembolic complications associated with l-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55(4), 702-706 (1985).
100. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98(10), 708-714 (2006). The most comprehensive assembly of published reports on the adverse effect of erythropoietin-stimulating agents.
101. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin. Cancer Res. 12(2), 332-339 (2006).
102. Inthal A, Krapf G, Beck D et al. Role of the erythropoietin receptor in ETV6/ RUNX1-positive acute lymphoblastic leukemia. Clin. Cancer Res. 14(22), 7196-7204 (2008).
103. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 75(2), 368-371 (1996).
104. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 23(10), 991-996 (1999).
105. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colonystimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 33(2), 171-176 (2004).
106. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 68(1), 39-42 (1982).
107. Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: Updates. Curr. Opin. Oncol. 16(6), 553-563 (2004).
108. Nowak-Gottl U, Ahlke E, Fleischhack G et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): Prednisone versus dexamethasone administration. Blood 101(7), 2529-2533 (2003).
109. Hashimoto S, Koike T, Tatewaki W et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 8(7), 1113-1115 (1994).
110. Brown JE, Olujohungbe A, Chang J et al. All-trans retinoic acid (ATRA) and tranexamic acid: A potentially fatal combination in acute promyelocytic leukaemia. Br. J. Haematol. 110(4), 1010-1012 (2000).
111. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92(8), 2712-2718 (1998). Of the published literature on the all-trans retinoic acid syndrome syndrome, this is probably the best description.
112. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95(1), 90-95 (2000).
113. Tallman MS. Retinoic acid syndrome: A problem of the past? Leukemia 16(2), 160-161 (2002).
114. McKoy JM, Angelotta C, Bennett CL et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. Leuk. Res. 31(5), 599-604 (2007).
115. Slats AM, Egeler RM, van der Does-van den Berg A et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): The Dutch Childhood Oncology Group experience. Leukemia 19(4), 537-544 (2005).
116. Athale UH, Chan AK. Hemorrhagic complications in pediatric hematologic malignancies. Semin. Thromb. Hemost. 33(4), 408-415 (2007).
117. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of platelets: Current problems and possible resolutions. Transfus. Med. Rev. 19(4), 259-272 (2005).
118. Ness P, Braine H, King K et al. Singledonor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 41(7), 857-861 (2001).
119. Triulzi DJ. Transfusion-related acute lung injury: Current concepts for the clinician. Anesth. Analg. 8(3), 770-776 (2009).
120. Kleinman S, Caulfield T, Chan P et al. Toward an understanding of transfusionrelated acute lung injury: Statement of a consensus panel. Transfusion 44(12), 1774-1789 (2004).
121. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br. J. Haematol. 136(6), 788-799 (2007). (Pubitemid 46348408)
122. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus. Med. Rev. 14(2), 180-196 (2000).
123. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am. Soc. Hematol. Educ. Program 172-178 (2007). Contains important guidelines on platelet transfusion.
124. Chambers LA, Herman JH. Considerations in the selection of a platelet component: Apheresis versus whole blood-derived. Transfus. Med. Rev. 13(4), 311-322 (1999).
125. Slichter SJ, Kaufman RM, Assmann SF et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N. Engl. J. Med. 362(7), 600-613 (2010). The latest results of a prospective clinical trial on various doses of platelets.
126. Estcourt LJ, Stanworth SJ, Murphy MF. Prophylactic platelet transfusions. Curr. Opin. Hematol. 17(5), 411-417 (2010).
127. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: A systematic review. Transfusion 8(7), 1447-1458 (2008).
128. Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis and platelet function testing. Br. J. Surg. 95(11), 1317-1330 (2008).
129. Slichter SJ, Davis K, Enright H et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105(10), 4106-4114 (2005).
130. Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch. Pathol. Lab. Med. 124(5), 730-734 (2000).
131. Tornebohm E, Lockner D, Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972-1991. Eur. J. Haematol. 50(3), 160-167 (1993).
132. Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Sem. Thromb. Hemostas. 36(5), 917-924 (2010).